Co-founded by Versant, NEA investors, new medtech VC firm kicks off inaugural fund with $225M bounty
In an era where medtech doesn’t get the same love that biotech does from the average investor, two medtech-focused investors from a pair of keystone venture capital firms — Versant Ventures and New Enterprise Associates (NEA) — are coming together to bridge the gap in private market capital for the underserved sector.
Launched this year, the VC investment firm — called Vensana Capital — closed its inaugural fund, Vensana Capital I, with $225 million in committed capital from a cadre of institutional investors, including public pensions, university endowments, foundations, leading academic health systems, family offices, and fund-of-funds, it said on Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.